Darutoside

Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis^[1][2][3]. In Vitro:Darutoside (0.1-1 mg/mL, 12 h) significantly inhibits the migration of RAW264.7 macrophages induced by LPS (HY-D1056)^[1].
Darutoside (0.1-10 μM, 24 h) inhibits the M1-type macrophage polarization by suppressing the NF-κB signaling pathway (reducing the levels of p-IkK, p-IkB, and p-p65) ^[2].
In Vivo:Darutoside (0.2-2 mg/kg, local topical application, once a day for a total of 5 days) significantly reduces ear and paw edema in mice and decreases the number of convulsions induced by Acetic acid (HY-Y0319)¹.
Darutoside (10-100 μM, local topical application, once daily for a total of 7 days) inhibits local inflammatory responses and significantly promotes wound healing in mouse skin^[2].
Darutoside (40 mg/mL, p.o., 2 h before modeling, 6 h and 22 h after modeling for 3 doses) significantly alleviates acute gouty arthritis in rats by inhibiting inflammatory cell infiltration and release, promoting blood circulation and improving immunity^[3].